Apogee Therapeutics (APGE) EPS (Weighted Average and Diluted) (2022 - 2026)
Apogee Therapeutics (APGE) reported EPS (Weighted Average and Diluted) of -$1.06 for Q1 2026, down 11.58% year-over-year from -$1.2 in Q1 2025, and down 2.91% on a QoQ basis from -$1.03 in Q4 2025.
Apogee Therapeutics (APGE) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.06 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 11.58% year-over-year to -$1.06 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.33 (down 20.28% YoY) and the FY2025 annual result came in at -$4.22, down 27.88% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$1.06 in Q1 2026 per APGE's latest filing, from -$1.03 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.84 in Q4 2022 and bottomed at -$9.46 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.04 (2025), against an average of -$1.61.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) surged 94.61%; it then slumped 271.88% in 2024.
- Tracing APGE's EPS (Weighted Average and Diluted) over 5 years: stood at $0.84 in 2022, then tumbled by 138.1% to -$0.32 in 2023, then tumbled by 271.88% to -$1.19 in 2024, then grew by 13.45% to -$1.03 in 2025, then declined by 2.91% to -$1.06 in 2026.
- Per Business Quant, the three latest APGE EPS (Weighted Average and Diluted) figures stand at -$1.06 (Q1 2026), -$1.03 (Q4 2025), and -$1.11 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | -1.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.06 |
| Dec 31, 2025 | -1.03 |
| Sep 30, 2025 | -1.11 |
| Jun 30, 2025 | -1.13 |
| Mar 31, 2025 | -0.95 |
| Dec 31, 2024 | -1.19 |
| Sep 30, 2024 | -0.86 |
| Jun 30, 2024 | -0.60 |
| Mar 31, 2024 | -0.64 |
| Dec 31, 2023 | -0.32 |
| Sep 30, 2023 | -0.51 |
| Jun 30, 2023 | -3.78 |
| Mar 31, 2023 | -2.51 |
| Dec 31, 2022 | 0.84 |
| Sep 30, 2022 | -9.46 |
| Jun 30, 2022 | -1.45 |